Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
Study for subjects with Chronic HCV with advanced liver disease using study drug combination (Sofosbuvir/Ledipasvir + Ribavirn)
Sponsor: Gilead Science Inc.
Enrolling: Male and Female Patients
IRB Number: AAAM2412
U.S. Govt. ID: NCT02010255
Contact: Theresa Lukose: 212-305-3839 / tt2103@columbia.edu
Additional Study Information: The purpose of this study is to see if study drug Sofosbuvir/Ledipasvir fixed-dose combination + Ribavirin (SOF/LDV FDC + RBV) are effective in treating people infected with the hepatitis C virus with genotypes 1 and 4, who have advanced liver disease with permanent liver damage (cirrhosis) and may be showing signs of liver failure or who have undergone liver transplantation, as well as evaluate the safety and tolerability of SOF/LDV FDC + RBV in these patients.
This study is closed
Investigator
Robert Brown, MD, MPH
Do You Qualify?
Do you have a Chronic Hepatitis C infection? Yes No
Have you been treated with anti-Hepatitis C medication in the last 30 days? Yes No
Do you have a history of alcohol abuse? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Theresa Lukose
tt2103@columbia.edu
212-305-3839
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE